Novo Nordisk (NVO) (OTCPK:NONOF) on Thursday announced a new initiative to promote its blockbuster weight loss therapy Wegovy ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy ® (semaglutide), which includes ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.